Hexarelin stimulates GH secretion in humans. That does not mean it has been shown to improve strength or recovery in a healthy adult. A sixteen-week human study observed no significant change in lean mass. “More powerful” sometimes describes a hormonal signal. It does not mean “better supported by evidence”.
Peptide marketing loves adding muscles to a lab graph. To make a decision, separate three questions: which hormone changes, which benefit is measured and what safety is documented? The answers are not interchangeable.
This documentary analysis offers neither purchasing advice nor guidance for self-injection. French and anti-doping status was checked on 14 October 2026. The searches described below identified no French medicine containing this molecule. WADA explicitly names it among substances prohibited at all times.
Hexarelin, GHRP-6 and ipamorelin: what sets them apart
Hexarelin, also called hexarelin or examorelin, is a synthetic peptide made up of six amino acids belonging to the GH secretagogue family. A secretagogue stimulates endogenous secretion. It is therefore neither pharmaceutical GH nor proof of a deficiency that needs correcting.
Its endocrine action involves the GH secretagogue receptor, GHSR-1a, also called the ghrelin receptor. The human experiments on hexarelin and its analogues document a GH response, but also prolactin, ACTH and cortisol responses. The effect is not a muscle-only switch.
GHRP-6 belongs to the same family, but the molecules are not identical. The guide to GHRP-6, its effects and its French status lets you compare the questions studied without transferring findings from one peptide to another.
Ipamorelin is often presented as more selective. The landmark pharmacological study from 1998 notably examines rat pituitary cells and pigs. Its experimental hormonal selectivity does not demonstrate better long-term safety in athletes. The authors were affiliated with Novo Nordisk, which places the development context. The guide to ipamorelin and CJC-1295 explores this distinction further.
| Molecule | Useful mechanistic question | Conclusion not to draw |
|---|---|---|
| Hexarelin | GH stimulation, other hormones and research on CD36 | Better recovery because the hormonal response is strong |
| GHRP-6 | Another peptide in the secretagogue family | Results and risks identical to those of hexarelin |
| Ipamorelin | Hormonal selectivity studied mainly in preclinical research in the landmark publication | Superior safety established for self-directed users |
Human studies: endpoints matter more than superlatives
In a 1999 experiment involving seven young adults, hexarelin and GHRP-2 produce comparable hormonal responses. The comparison also includes an analogue, Tyr-Ala-hexarelin. Neither strength gains nor time to return to training is assessed. This study therefore cannot award the title of best sports peptide.
The most directly useful work for testing the body-composition promise is that of Rahim and colleagues, published in 1998. After sixteen weeks of repeated administration in older people, the GH response partially diminishes. It returns towards its initial level four weeks after discontinuation. IGF-1, lean mass, fat mass and bone mineral density do not change significantly.
This finding provides a concrete challenge to the hormonal shortcut. It does not demonstrate ineffectiveness in all populations, and a small study cannot rule out a modest effect. However, it establishes no benefit in healthy adults looking to make progress in strength training.
There are also human cardiac observations. A study published in 2002 compares eight patients with dilated cardiomyopathy and five with ischemic cardiomyopathy with previously studied groups. An acute effect on ejection fraction appears in the ischemic group, but not in the dilated group. This measures neither hospitalizations avoided, survival nor athletic endurance. An acute cardiac signal does not justify any cardiovascular self-medication.
Evidence matrix
This selection links each finding to its population, without claiming to constitute a systematic review:
| Study | Population or model | Endpoint | Finding | Key limitation |
|---|---|---|---|---|
| 1999, endocrine comparison | 7 young adults | GH, prolactin, ACTH, cortisol after acute exposure | Hormonal stimulation | No strength or recovery measured |
| 1998, repeated exposure | Older people, 16 weeks | GH response, IGF-1, body composition | Diminished GH response, no significant change in lean mass | Limited population and duration, no validation for sports use |
| 1999, endocrine follow-up | Older people, 16 weeks | Hypothalamic–pituitary–adrenal axis and prolactin | No chronic overstimulation under this regimen | Does not demonstrate general safety |
| 2002, cardiac function | 8 patients with dilated cardiomyopathy, 5 with ischemic cardiomyopathy | Acute ejection fraction | Response differs by disease | No lasting clinical benefit established |
| 2023, neuroblastoma | Modified human cell line | Viability, oxidative stress, apoptosis | Protective signals in culture | No patient treated |
| 2017, metabolism | Insulin-resistant male MKR mice, 12 days | Metabolism and body composition | Improvements in this model | No evidence in healthy athletes |
| 2026, pancreas | 50 male mice, MPTP model | Histology and tissue markers | Attenuation of certain lesions | Incomplete temporal control, no patient |
| 2024, viral infection | Infected K18-hACE2 mice | Survival and inflammatory response | Favorable signal in the model | Neither a human trial nor athletic recovery |
Cells, mice and CD36: four different evidence sets
GH means growth hormone. IGF-1 refers to a mediator of certain GH actions. CD36, or cluster of differentiation 36, is a receptor involved notably in interactions with lipids and in the response of certain immune cells. CD36 is not another name for the ghrelin receptor.
The 2024 study in K18-hACE2 mice infected with SARS-CoV-2 examines hexarelin as a CD36 ligand in a particular inflammatory context. The figures notably report improved survival in this model. This finding warrants a research question. It does not justify a Covid-19 treatment or a general anti-inflammatory promise in humans.
The finding often cited under reference PMC5659698 concerns non-obese, insulin-resistant male MKR mice studied in 2017. Over twelve days, the researchers report improvements in metabolic and body-composition parameters. This disease model does not represent a healthy athlete. It demonstrates neither a human treatment for insulin resistance nor muscle gains transferable to your training.
A September 2026 publication examines fifty male mice exposed to MPTP, divided into five groups. It reports attenuation of certain histological and immunohistochemical pancreatic changes. The authors specify an important limitation: the lack of a vehicle control matched to the sequence and time after MPTP prevents a complete separation of the effect associated with hexarelin from changes over time. Even this recent finding remains preclinical. A publication date does not turn a mouse into a patient.
The 2023 publication on a human neuroblastoma cell line expressing SOD1-G93A measures cellular markers of protection. “Human” here describes the origin of cultured cells, not trial participants. No neurological benefit in a person can be inferred from it.
Four levels to keep separate
A protected cell does not demonstrate human recovery
- Cells: viability and molecular pathways
- Mice: effects in an experimental model
- Humans: hormonal response or physiological measurement
- Clinical benefits: strength, recovery and safety still to be demonstrated
That is the trap of Mitochondria Marketing : using a real biological mechanism to sell a benefit that has not been demonstrated. Here, the biology exists. The leap to guaranteed recovery remains unproven.
Hormonal risks and safety: what the data do not establish
Acute human experiments document activation of the hypothalamic–pituitary–adrenal axis, with ACTH and cortisol measurements. The hormonal response is a pharmacological finding. On its own, it does not provide a rate of clinical adverse effects.
The finding that qualifies this concern must also be reported. The sixteen-week follow-up published in 1999 finds no chronic overstimulation of the hypothalamic–pituitary–adrenal axis or prolactin under the regimen studied. The cortisol response decreases, while urinary free cortisol does not change significantly. Claiming that every exposure necessarily leads to constantly elevated cortisol would therefore be excessive.
These observations do not document the safety of months or years of self-directed use, peptide combinations or products of unknown composition. The selected studies do not allow robust quantification of long-term metabolic, cardiovascular, reproductive or tumor-related risks. A commercial list of side effects does not fill that gap.
Pregnancy, breastfeeding, being underage, diabetes, pituitary disease and a history of tumors call for a medical discussion, not experimentation. These are situations requiring caution, not contraindications taken from the summary of product characteristics of a French hexarelin medicine: none was identified. Interactions are not sufficiently characterized to call a peptide mixture safe.
Research vials: chemical purity and injection safety
An HPLC certificate provides information about chromatographic separation performed on a sample. Its interpretation depends on the method, detectable substances and traceability. A relative purity percentage does not automatically demonstrate the correct quantity, complete identity or representativeness of the vial delivered.
The ICH Q6A pharmaceutical specifications distinguish chemical characteristics from sterility, endotoxin and particle testing for parenteral products. These questions require separate assessments. Even an authentic analytical document does not constitute authorization for human administration.
The label “research use only” describes an intended research purpose. It does not turn the product into a medicine. The guide to online peptides, contamination and sterility · FR explains why no purity argument gets around this distinction.
Status in France and anti-doping: check of 14 October 2026
Scope of the official check. The files CIS_bdpm.txt and CIS_COMPO_bdpm.txt, downloaded from the BDPM, were searched using the roots “hexar”, “examorel” and “examorél”. No match was found. No medicine containing hexarelin or examorelin was therefore identified within this scope.
The BDPM covers medicines currently marketed or whose marketing was recently discontinued. This absence does not exhaustively prove the absence of historical authorization, research or exceptional access. Nor does it automatically establish that any possession is an offense. For an import or a particular medical situation, ask a pharmacist or the ANSM to check.
The ANSM alert of 2 July 2026, reproduced by the French National Order of Pharmacists, advises against buying and using peptides sold online outside official channels. This is a general alert, not a pharmacovigilance study specific to hexarelin. The source consulted here is the Order’s institutional republication.
Anti-doping. The 2026 WADA list, section S2.2.4, explicitly names examorelin (hexarelin) among GH-releasing peptides. The prohibition applies in and out of competition. Easy access to purchase or uncertain sporting effectiveness does not change this rule.
Prepare for a consultation, without inventing a protocol
Persistent fatigue, pain and stalled strength gains do not raise the same medical question. Describe the problem, its duration and how it has developed before looking for a molecule. To make the consultation useful, prepare these questions:
- What cause could explain my symptoms or impaired recovery?
- Which study measures a benefit relevant to me in a comparable population?
- Does my clinical history warrant an endocrine investigation?
- Do my medications, medical history and anti-doping obligations change the decision?
- Is there an authorized treatment for the problem identified?
Experimental exposure does not provide a personal dose: formulation, participant selection and monitoring change the scope of the findings. The observed desensitization validates neither peptide rotation nor a restart cycle. I do not propose an administration regimen.
If you have already used a product, tell the doctor its name, when you were exposed and what other substances you took. Keep the packaging and batch reference. A significant reaction or persistent symptoms require assessment. In France, difficulty breathing, facial swelling or loss of consciousness warrants calling 15 or 112.
The Verdict
Sources and method
Targeted literature search, completed on 14 October 2026. The cited human and preclinical publications were examined through their indexed abstracts (PubMed and Europe PMC) and, for cell and mouse studies, the figure legends available on PubMed. Not all full-text articles were consulted. This selection is not a systematic review and does not claim to have undergone independent medical review:
